HUMA Stock Overview
Engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Humacyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.31 |
| 52 Week High | US$9.97 |
| 52 Week Low | US$1.15 |
| Beta | 1.62 |
| 1 Month Change | -10.27% |
| 3 Month Change | -71.40% |
| 1 Year Change | -70.29% |
| 3 Year Change | -79.14% |
| 5 Year Change | n/a |
| Change since IPO | -86.45% |
Recent News & Updates
Recent updates
Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)
Mar 24Humacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A Beginning
Jan 08Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)
Dec 23Humacyte: FDA Waiting Game Bleeding Company Dry
Dec 14Humacyte: Navigating The FDA Uncertainty And ATEV's Potential
Sep 24Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Aug 16
Humacyte: Pioneering Vascular Solutions With High-Stakes Potential
Jul 17Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation
Jun 05Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High
May 14Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Feb 14Shareholder Returns
| HUMA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.0% | 2.7% | 2.9% |
| 1Y | -70.3% | -6.7% | 10.0% |
Return vs Industry: HUMA underperformed the US Biotechs industry which returned -6.7% over the past year.
Return vs Market: HUMA underperformed the US Market which returned 10% over the past year.
Price Volatility
| HUMA volatility | |
|---|---|
| HUMA Average Weekly Movement | 17.6% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: HUMA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HUMA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 219 | Laura Niklason | humacyte.com |
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Humacyte, Inc. Fundamentals Summary
| HUMA fundamental statistics | |
|---|---|
| Market cap | US$218.72m |
| Earnings (TTM) | -US$148.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs HUMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HUMA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$88.60m |
| Gross Profit | -US$88.60m |
| Other Expenses | US$60.10m |
| Earnings | -US$148.70m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -122.0% |
How did HUMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/02 03:46 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Humacyte, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Michael Gorman | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |